Stoke Therapeutics, Inc. $STOK Shares Sold by Trexquant Investment LP

Trexquant Investment LP reduced its holdings in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) by 16.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 86,140 shares of the company’s stock after selling 16,891 shares during the period. Trexquant Investment LP owned approximately 0.16% of Stoke Therapeutics worth $573,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its position in Stoke Therapeutics by 1,842.0% during the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company’s stock valued at $36,000 after buying an additional 5,084 shares in the last quarter. AlphaQuest LLC acquired a new position in Stoke Therapeutics during the 1st quarter valued at about $72,000. US Bancorp DE increased its position in Stoke Therapeutics by 9,743.9% during the 1st quarter. US Bancorp DE now owns 11,222 shares of the company’s stock valued at $75,000 after buying an additional 11,108 shares in the last quarter. ProShare Advisors LLC acquired a new position in Stoke Therapeutics during the 4th quarter valued at about $139,000. Finally, Fox Run Management L.L.C. acquired a new position in shares of Stoke Therapeutics in the first quarter valued at about $92,000.

Insider Activity at Stoke Therapeutics

In related news, Director Edward M. Md Kaye sold 45,996 shares of the stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $20.13, for a total value of $925,899.48. Following the completion of the sale, the director owned 91,585 shares of the company’s stock, valued at approximately $1,843,606.05. This trade represents a 33.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Jonathan Allan sold 6,345 shares of the stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $20.07, for a total value of $127,344.15. Following the completion of the sale, the general counsel directly owned 11,831 shares of the company’s stock, valued at approximately $237,448.17. This represents a 34.91% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 107,719 shares of company stock valued at $2,063,359. 9.50% of the stock is currently owned by insiders.

Stoke Therapeutics Trading Up 6.3%

Shares of STOK stock opened at $21.99 on Tuesday. The company has a market capitalization of $1.21 billion, a P/E ratio of 25.87 and a beta of 1.14. The business’s 50 day moving average is $15.13 and its two-hundred day moving average is $11.15. Stoke Therapeutics, Inc. has a 12-month low of $5.35 and a 12-month high of $22.39.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.17. The company had revenue of $13.82 million for the quarter, compared to the consensus estimate of $31.51 million. Stoke Therapeutics had a return on equity of 18.32% and a net margin of 26.25%. On average, research analysts predict that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

STOK has been the topic of a number of research reports. Needham & Company LLC reissued a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a report on Tuesday, July 1st. Cantor Fitzgerald raised Stoke Therapeutics to a “strong-buy” rating in a report on Wednesday, May 14th. HC Wainwright cut their price objective on Stoke Therapeutics from $47.00 to $35.00 and set a “buy” rating on the stock in a report on Wednesday, May 14th. Jefferies Financial Group initiated coverage on Stoke Therapeutics in a report on Friday, July 18th. They issued a “buy” rating and a $30.00 price objective on the stock. Finally, Chardan Capital reissued a “buy” rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, August 13th. Two research analysts have rated the stock with a Strong Buy rating and seven have given a Buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $25.57.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.